Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triacetin SCHEMBL3870 | 0.74 | TDP1 (0.56) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL821340 | 0.74 | TDP1 (0.56) | TDP1GAAARPRKCAKMT2A | |
| SCHEMBL3975559 | 0.73 | SLC18A3 (0.43) | TDP1GAAARPOLBMAPT | |
| Triacetin SCHEMBL31301065 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL16446056 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL31035933 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL4367394 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL8012678 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL30661717 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A | |
| Triacetin SCHEMBL16445622 | 0.72 | TDP1 (0.54) | TDP1GAAARPRKCAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | ACP1, LTK, TTL | TDP1 1088/4885GAA 406/4885AR 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.